Previous close | 1.5800 |
Open | 1.5800 |
Bid | 0.0000 x 1000 |
Ask | 1.5900 x 1400 |
Day's range | 1.5800 - 1.5900 |
52-week range | 1.5800 - 4.0400 |
Volume | |
Avg. volume | 50,444 |
Market cap | 87.822M |
Beta (5Y monthly) | 1.99 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.5900 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.50 |
Cellectis, which gets a seat on Primera's board, will collaborate with Primera on the development of therapies for mitochondrial diseases, a group of genetic disorders. Under terms of the deal, if Primera chooses to exclusively license up to five co-developed therapies from Cellectis, it will be eligible to get up to $750 million in milestone payments.
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.